Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone
Sign Up to like & getrecommendations! Published in 2020 at "Advances in Therapy"
DOI: 10.1007/s12325-020-01260-x
Abstract: Introduction Prostate cancer (PC) is the second leading cause of cancer death among US men and accounts for considerable healthcare expenditures. We evaluated economic outcomes in men with chemotherapy-naïve metastatic castration-resistant PC (mCRPC) treated with… read more here.
Keywords: cause; enzalutamide abiraterone; treated enzalutamide; castration ... See more keywords
Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Prostate cancer and prostatic diseases"
DOI: 10.1038/s41391-021-00463-9
Abstract: BACKGROUND Black men are more likely to be diagnosed with aggressive prostate cancer (PC) and die from PC than white men. However, black men with metastatic castration-resistant PC (mCRPC) had longer overall survival (OS) than… read more here.
Keywords: white men; enzalutamide abiraterone; prostate cancer; castration ... See more keywords
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of Oncology"
DOI: 10.1093/annonc/mdx155
Abstract: Abstract Background There is an urgent need to identify biomarkers to guide personalized therapy in castration-resistant prostate cancer (CRPC). We aimed to clinically qualify androgen receptor (AR) gene status measurement in plasma DNA using multiplex… read more here.
Keywords: status; plasma; plasma dna; enzalutamide abiraterone ... See more keywords